Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | PKLR | P30613 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.33 |
| ▸ | ATXN2 | Q99700 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | PLAU | P00749 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL781954 | 1.00 | ALDH1A1 (0.40) | ALDH1A1LMNAMAPK1SMN1; SMN2PKM | |
| SCHEMBL12238818 | 0.91 | ALDH1A1 (0.39) | ALDH1A1LMNAMAPK1SMN1; SMN2PKM | |
| SCHEMBL781526 | 0.90 | ALDH1A1 (0.38) | ALDH1A1LMNAMAPK1SMN1; SMN2PKM | |
| SCHEMBL781524 | 0.90 | ALDH1A1 (0.38) | ALDH1A1LMNAMAPK1SMN1; SMN2PKM | |
| SCHEMBL10189538 | 0.90 | PKM (0.37) | ALDH1A1LMNAMAPK1SMN1; SMN2PKM | |
| SCHEMBL781732 | 0.89 | PKM (0.38) | ALDH1A1LMNAMAPK1SMN1; SMN2PKM | |
| SCHEMBL781730 | 0.89 | PKM (0.38) | ALDH1A1LMNAMAPK1SMN1; SMN2PKM | |
| Succinic Acid SCHEMBL781781 | 0.88 | ALDH1A1 (0.36) | ALDH1A1LMNAMAPK1SMN1; SMN2PKM | |
| Succinic Acid SCHEMBL781782 | 0.88 | ALDH1A1 (0.36) | ALDH1A1LMNAMAPK1SMN1; SMN2PKM | |
| SCHEMBL2125195 | 0.88 | ALDH1A1 (0.39) | ALDH1A1LMNAMAPK1SMN1; SMN2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2828261-A1 | CRYSTALLINE FORM OF A SUCCINATE SALT | Novartis AG (CH) | 2015-01-28 | — | — | EP | claimed |
| WO-2013140319-A9 | CRYSTALLINE FORM OF A SUCCINATE SALT | NOVARTIS AG (CH) | 2014-01-03 | — | — | WO | claimed |
| WO-2013140319-A1 | CRYSTALLINE FORM OF A SUCCINATE SALT | NOVARTIS AG (CH) | 2013-09-26 | — | — | WO | claimed |
| EP-2616447-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | Novartis AG (CH) | 2013-07-24 | — | — | EP | claimed |
| WO-2012035158-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | claimed |
| US-10206877-B2 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-02-19 | — | — | US | disclosed |
| US-20170143705-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | NOVARTIS AG (CH) | 2017-05-25 | — | — | US | disclosed |
| EP-3131582-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | Vertex Pharmaceuticals Incorporated (US) | 2017-02-22 | — | — | EP | disclosed |
| US-9522149-B2 | Pyrazine derivatives as ENaC blockers | NOVARTIS AG (CH) | 2016-12-20 | — | — | US | disclosed |
| EP-2828261-B1 | Crystalline form of a succinate salt | NOVARTIS AG (CH) | 2016-02-03 | — | — | EP | disclosed |
| US-20150320736-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | VERTEX PHARMACEUTICALS INCORPORATED | 2015-11-12 | — | — | US | disclosed |
| WO-2015160787-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-10-22 | — | — | WO | disclosed |
| EP-2828261-A1 | CRYSTALLINE FORM OF A SUCCINATE SALT | Novartis AG (CH) | 2015-01-28 | — | — | EP | disclosed |
| US-20140113914-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | NOVARTIS AG (CH) | 2014-04-24 | — | — | US | disclosed |
| WO-2013140319-A9 | CRYSTALLINE FORM OF A SUCCINATE SALT | NOVARTIS AG (CH) | 2014-01-03 | — | — | WO | disclosed |
| WO-2013140319-A1 | CRYSTALLINE FORM OF A SUCCINATE SALT | NOVARTIS AG (CH) | 2013-09-26 | — | — | WO | disclosed |
| EP-2616447-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | Novartis AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| US-8372845-B2 | Pyrazine derivatives as enac blockers | NOVARTIS AG (CH) | 2013-02-12 | — | — | US | disclosed |
| WO-2012035158-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
| US-20120071479-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | NOVARTIS AG (CH) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150320736-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | CFTR, SLC26A4, PKD1 | ALDH1A1 2648/4885LMNA 3070/4885MAPK1 4396/4885 |
| US-20140113914-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | REN, SCNN1B, SCN5A | ALDH1A1 2428/4885LMNA 2950/4885MAPK1 2369/4885 |
| US-20170143705-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | REN, SCNN1B, SCN5A | ALDH1A1 2428/4885LMNA 2950/4885MAPK1 2369/4885 |
| US-20120071479-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | REN, SCNN1B, SCN5A | ALDH1A1 2428/4885LMNA 2950/4885MAPK1 2369/4885 |
| US-10206877-B2 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | CFTR, SLC26A4, PKD1 | ALDH1A1 2648/4885LMNA 3070/4885MAPK1 4396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.